trending Market Intelligence /marketintelligence/en/news-insights/trending/X1Pq1YY3HJgK_yDqXEYaWA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Imugene to advance gastric cancer vaccine to phase 2 after positive results

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Imugene to advance gastric cancer vaccine to phase 2 after positive results

Imugene Ltd.'s gastric cancer vaccine HER-Vaxx was found to be safe and tolerable in an early-stage study, which the company said will support the advancement of the drug to a phase 2 trial.

HER-Vaxx is an add-on vaccine therapy for gastric cancer designed to trigger an immune response against cancer cells that overexpress a gene called HER-2. During the phase 1b trial, 14 participants tested doses of HER-Vaxx in combination with the typical standard of care, which includes certain chemotherapy drugs.

An increased antibody response in the patients was recorded for all dose levels. Five out of 10 patients who were examined more closely showed a partial response to the combination therapy, while four saw their disease stabilize, signifying that the cancer was neither growing or shrinking.

Based on the eight-week data from the trial, Imugene plans to enroll 68 gastric cancer patients in a phase 2 trial in 2019. The randomized phase 2 study will measure the overall survival and success of HER-Vaxx in preventing the disease's advance in patients.

According to the company, the phase 2 study will be conducted in Asia, Eastern Europe and India, where common therapies for this type of cancer made by Roche Holding AG unit Genentech Inc., Herceptin and Perjeta, are not readily available to patients.

SNL Image